Claim · 2025-11-05 · announcement · Stated in source · Supported

XtalPi announced on 5 November 2025 that its wholly-owned subsidiary Shanghai Ailux Biotechnology entered a strategic platform-based collaboration with Eli Lilly and Company on bispecific antibodies, with a total potential value of up to US$345 million.

One recorded claim. The claim panel gives its qualification, the source passages with their place in each source, and how it was checked.

What it connects

Ailux → announced a partnership with → Eli Lilly and Company

Where it appears

No collection page holds this claim. It is listed with its records in the explorer.

Claim and evidence

Ailuxannounced a partnership with ↓Eli Lilly and Company

Machine-checked, not reviewed by an editorStated in sourceSupported

Supporting evidence: primary · 1 source

Date: 2025-11-05 · announcement Records dated 2025 →
Activity stage: announced

Scope and limitsAnnounced terms as XtalPi states them; "up to" is conditional on milestones and is not a payment. The upfront and near-term amounts are stated only as "tens of millions US dollars".

The evidence 02

primary sourceSupports the claim

XtalPi Holdings Limited: Voluntary Announcement - XtalPi Subsidiary Ailux Announces Strategic Collaboration with Lilly to Advance (AI Driven) Bispecific Antibody Development

XtalPi Holdings Limited, published on HKEXnews · 2025-11-05

Cite the original source

Cite the original document, not Selekoa. Check these details against it.

Source excerpt

“entered into a strategic platform-based collaboration (the “Collaboration”) with Eli Lilly and Company (“Lilly”) to accelerate the discovery and development of bispecific antibodies”

Location in source first paragraph

How it was read Retrieved directly from the publisher

Machine-checked · 2026-10-30

Source details and check notes

Authors: XtalPi Holdings Limited, published on HKEXnews
Version: Retrieved for the candidate pack on 2026-10-30 (SHA-256 d5db504f0217262564a42ecc4b702b5491f9131582138d7683da41f5c87df0b3). HKEXnews PDF 2025110501768, announcement listed on 2025-11-05, as served on 2026-10-30.
Canonical address: Open the canonical source ↗
Accessed: 2026-10-30
Language: English (en)
Attribution: XtalPi Holdings Limited, published on HKEXnews, “XtalPi Holdings Limited: Voluntary Announcement - XtalPi Subsidiary Ailux Announces Strategic Collaboration with Lilly to Advance (AI Driven) Bispecific Antibody Development”, 2025-11-05.
Reuse: No open redistribution licence asserted. Bibliographic metadata, editorial paraphrases and short attributed quotations (at most 50 words each). Recheck terms before wider redistribution.
Check notes: Candidate pack passage, AI in biology (research/ai-in-biology). The quotation (23 words) matched the text retrieved for the candidate pack on 2026-10-30. Matching ignored differences of whitespace, case, quotation marks, dashes and Unicode compatibility forms, so the source’s typography can differ. A cross-family machine check (2026-10-30, item A30) answered the record’s question blind from fresh retrievals and agreed with the record. No human editorial review.

primary sourceSupports the claim

XtalPi Holdings Limited: Voluntary Announcement - XtalPi Subsidiary Ailux Announces Strategic Collaboration with Lilly to Advance (AI Driven) Bispecific Antibody Development

XtalPi Holdings Limited, published on HKEXnews · 2025-11-05

Cite the original source

Cite the original document, not Selekoa. Check these details against it.

Source excerpt

“is up to US$345 million.”

Location in source third paragraph

How it was read Retrieved directly from the publisher

Machine-checked · 2026-10-30

Source details and check notes

Authors: XtalPi Holdings Limited, published on HKEXnews
Version: Retrieved for the candidate pack on 2026-10-30 (SHA-256 d5db504f0217262564a42ecc4b702b5491f9131582138d7683da41f5c87df0b3). HKEXnews PDF 2025110501768, announcement listed on 2025-11-05, as served on 2026-10-30.
Canonical address: Open the canonical source ↗
Accessed: 2026-10-30
Language: English (en)
Attribution: XtalPi Holdings Limited, published on HKEXnews, “XtalPi Holdings Limited: Voluntary Announcement - XtalPi Subsidiary Ailux Announces Strategic Collaboration with Lilly to Advance (AI Driven) Bispecific Antibody Development”, 2025-11-05.
Reuse: No open redistribution licence asserted. Bibliographic metadata, editorial paraphrases and short attributed quotations (at most 50 words each). Recheck terms before wider redistribution.
Check notes: Candidate pack passage, AI in biology (research/ai-in-biology). The quotation (5 words) matched the text retrieved for the candidate pack on 2026-10-30. Matching ignored differences of whitespace, case, quotation marks, dashes and Unicode compatibility forms, so the source’s typography can differ. A cross-family machine check (2026-10-30, item A30) answered the record’s question blind from fresh retrievals and agreed with the record. No human editorial review.

Status and meaning

Editorial status. Not reviewed by an editor. An exploratory record that no editor has accepted. This status does not say whether a person has read any linked passage. Each evidence record above shows how it was checked.

Relation. An organisation announced a collaboration or partnership with a named counterparty, as the announcement states it (stage announced). It is not evidence that the work was performed, that a payment was made or that the arrangement continues; an “up to” amount stays in the statement.

Date. Date of the HKEXnews listing of XtalPi's announcement.

Record ID aib-co-ailux-lilly-2025